Cargando…

Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience

Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocorocchio, E, Gandini, S, Alfieri, S, Battaglia, A, Pennacchioli, E, Tosti, G, Spadola, G, Barberis, M, Leo, M Di, Riviello, C, Pala, L, Intelisano, A, Martinoli, C, Ferrucci, PF
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778691/ https://www.ncbi.nlm.nih.gov/pubmed/26981153 http://dx.doi.org/10.3332/ecancer.2016.624

Ejemplares similares

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
por: Ferrucci, P F, et al.
Publicado: (2015)

Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy
por: Gandini, Sara, et al.
Publicado: (2013)

Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
por: Tosti, Giulio, et al.
Publicado: (2013)

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2017)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Combination of dabrafenib and radiotherapy: could skin toxicity be affected by different irradiation techniques?
por: Alterio, Daniela, et al.
Publicado: (2016)

Successful treatment with avapritinib in patient with mucosal metastatic melanoma
por: Cocorocchio, Emilia, et al.
Publicado: (2020)

Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial
por: Johansson, Harriet, et al.
Publicado: (2021)

Dabrafenib and its potential for the treatment of metastatic melanoma
por: Menzies, Alexander M, et al.
Publicado: (2012)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
por: Valpione, Sara, et al.
Publicado: (2015)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Novel Biomarkers and Druggable Targets in Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
por: Atkinson, Victoria G., et al.
Publicado: (2021)

Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020)

Successful Dabrafenib Desensitization Protocols in a Patient with Metastatic Melanoma
por: Bumbacea, Roxana Silvia, et al.
Publicado: (2022)

Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
por: McGettigan, Suzanne
Publicado: (2014)

Phenotype characterization of human melanoma cells resistant to dabrafenib
por: Cordaro, Fabiola Gilda, et al.
Publicado: (2017)

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
por: Luke, Jason J, et al.
Publicado: (2014)

Retinal Vein Occlusion in a Patient on Dabrafenib and Trametinib Therapy for Metastatic Melanoma
por: Molero-Senosiain, Mercedes, et al.
Publicado: (2022)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Shalata, Walid, et al.
Publicado: (2023)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G. V., et al.
Publicado: (2017)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G V, et al.
Publicado: (2019)

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
por: Draganova, Dafina, et al.
Publicado: (2015)

Identification of Key miRNAs in the Treatment of Dabrafenib-Resistant Melanoma
por: Gao, Guangyu, et al.
Publicado: (2021)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

A Case of Intracranial Hemorrhage Caused by Combined Dabrafenib and Trametinib Therapy for Metastatic Melanoma
por: Lee, Le Min, et al.
Publicado: (2014)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature
por: Garrett, Giorgia L., et al.
Publicado: (2015)

Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib
por: Ross, Kayleigh C., et al.
Publicado: (2018)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
por: Banzi, Maria, et al.
Publicado: (2016)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Endoplasmic reticulum stress-induced autophagy determines the susceptibility of melanoma cells to dabrafenib
por: Ji, Chao, et al.
Publicado: (2016)

Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report
por: Sundaram, Vinita Ruth, et al.
Publicado: (2018)

Dabrafenib–Panobinostat Salt: Improving the Dissolution Rate and Inhibition of BRAF Melanoma Cells
por: Rai, Sunil K., et al.
Publicado: (2023)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma
por: Tahseen, Ahmed I., et al.
Publicado: (2018)

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report
por: Casadevall, David, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bv2bduf1mn9tf51hfv214lv2nm